Previous analyses of the drug research and development pipeline have shown that, between 1975 and 1999, only 1.1% of new therapeutic products were developed for poverty-related infectious and parasitic diseases. Since then, new initiatives including public funding, private philanthropy and product development partnerships have attempted to mitigate this imbalance. This study analyzes the state of the R&D pipeline for drugs and vaccines for neglected diseases between 2000 and 2011.
Jean-Hervé Bradol is Director of Studies at the Centre de Réflexion sur l'Action et les Savoirs Humanitaires (Crash, MSF Foundation, Paris) and a lecturer at Sciences-Po (IEP, Paris). He trained as a general practitioner, and also holds degrees in tropical medicine, emergency medicine and medical epidemiology. He first went on mission with Médecins Sans Frontières (MSF) in 1989, working in Uganda, Somalia, Tajikistan and Rwanda. Returning to Paris in 1994, he took up the post of Program Manager at MSF headquarters. From 1996 to 1998, he was Communications Director. In 1998, he became Director of Operations until he was elected President of MSF's French section in May 2000. He was re-elected in May 2003 and May 2006. From 2000 to 2008, he was a member of MSF's International Council and the Board of Directors of MSF USA.
